The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer
Open Access
Abstract
Prostate cancer is the second most frequently occurring cancer diagnosed among males. Recent preclinical evidence implicates cannabinoids as powerful regulators of cell growth and differentiation. In this review, we focused on studies that demonstrated anticancer effects of cannabinoids and their possible mechanisms of action in prostate cancer. Besides the palliative effects of cannabinoids, research from the past two decades has demonstrated their promising potential as antitumor agents in a wide variety of cancers. This analysis may provide pharmacological insights into the selection of specific cannabinoids for the development of antitumor drugs for the treatment of prostate cancer.Keywords
Funding Information
- MGC Pharmaceuticals Pty Ltd (Not Applicable)
This publication has 98 references indexed in Scilit:
- Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cellsCell Death & Disease, 2013
- Cannabinoid Receptor Type 1 (CB1) Activation Inhibits Small GTPase RhoA Activity and Regulates Motility of Prostate Carcinoma CellsEndocrinology, 2012
- The Significance of G Protein-Coupled Receptor Crystallography for Drug DiscoveryPharmacological Reviews, 2011
- Cannabinoids, endocannabinoids, and cancerCancer and Metastasis Reviews, 2011
- Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effectsBritish Journal of Pharmacology, 2011
- Cannabinoid CB1receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cellsBritish Journal of Pharmacology, 2011
- Cannabinoid CB1receptor‐interacting proteins: novel targets for central nervous system drug discovery?British Journal of Pharmacology, 2010
- Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2British Journal of Cancer, 2009
- Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disordersNature Reviews Drug Discovery, 2009
- Inflammation and cancerNature, 2002